Financial Performance - The company reported a significant increase in revenue, achieving a total of 50 million in sales within the first year[18]. - The company aims to continue executing its expansion plans to meet future demand for ophthalmic surgical treatments in Europe and China[115]. - In 2023, the company plans to open three new clinics in Germany to strengthen its market leadership[115]. - The company is focused on expanding its market presence and enhancing its service offerings in high-end vision correction services across Germany, China, Denmark, and the UK[196]. Acquisitions and Strategic Moves - A strategic acquisition of a local competitor was completed for $100 million, anticipated to enhance operational efficiency and market reach[18]. - The company completed the acquisition of London Vision Clinic Partners Limited for GBP 13.1 million (approximately HKD 138.2 million), with a potential maximum consideration of GBP 34.3 million (approximately HKD 322.6 million)[84]. - The acquisition of London Vision Clinic was completed for a maximum consideration of GBP 34.3 million (approximately HKD 322.6 million), enhancing the group's presence in the high-end refractive surgery market in London[186]. - The company appointed the founder of London Vision Clinic, Professor Dan Reinstein, as an executive director and member of the International Medical Advisory Committee to enhance expertise[130]. Operational Efficiency and Cost Management - The company aims to reduce operational costs by 10% through improved supply chain management and automation[21]. - Employee benefit expenses increased by 29.1% to 140.9 million HKD in 2022, up from 109.2 million HKD in 2021[198]. - The increase in total costs was primarily driven by a rise in surgeries performed at UK clinics, leading to higher employee benefit expenses and depreciation of property, plant, and equipment[198]. - The cost of materials and consumables decreased by 16.9% to 78.3 million HKD in 2022, compared to 94.3 million HKD in 2021, due to reduced surgical volumes and better procurement prices[198]. Risks and Challenges - The company faces risks related to operational failures, including potential claims due to treatment errors or equipment malfunctions[22]. - The ongoing impact of the Russia-Ukraine crisis has negatively affected consumer confidence in Europe, particularly among the younger generation[114]. Employee and Compensation Policies - The company has a fixed contribution rate of 5% of employee-related income for its mandatory provident fund plan in Hong Kong, with a monthly income cap of HKD 30,000[29]. - The board believes that the compensation provided to employees is competitive compared to market standards[44]. - The management team and key employees' continuous service is critical for the company's success, and losing them may incur additional costs for hiring and training replacements[33]. Environmental and Social Responsibility - The company emphasizes environmental principles and will continue to promote sustainable development through various measures[36]. - The company will regularly review its environmental principles and ensure compliance with relevant policies and regulations[36]. - The company is committed to providing the best customer experience for patients and actively seeks customer feedback through a patient survey system[38].
德视佳(01846) - 2022 - 年度财报